Filing Flows › Health Care › AtaiBeckley
AtaiBeckley earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026
Q2 2026 Revenue up 137% year over year to $1.7M
AtaiBeckley made $1.7M in Q2 2026 (+137% Y/Y): Research and Development Services Revenue $1.3M, License $437K. Operating margin n/m, net loss $32.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.7M in Q2 2026, up 137% year over year and up 79% from the previous quarter. Research and Development Services Revenue was the largest line at 74% of revenue. Research and Development Services Revenue added $548K year over year (up 76%), 56% of the total change.
Operating costs exceeded revenue by $44.1M, an operating margin of -2590.4%. Total costs grew 76% against revenue growth of 137%. The fastest-growing cost line was General & admin (+19%). The quarter ended with a net loss of $32.5M, wider than the previous quarter's $29.8M loss. Minority interests bore $24K of it: to shareholders the quarter was a loss of $32.5M. Non-operating items added $11.7M, -36% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$35.3M. Non-cash charges added back $215K of depreciation and amortization and $7.4M of share-based compensation. Working capital and other items used $10.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $1.7M | +137% | n/m | −$32.5M | −$35.3M |
| Q1 2026 | 10-Q | May 12, 2026 | $954K | -39% | n/m | −$29.8M | −$21.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About AtaiBeckley
Founded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, AtaiBeckley is a clinical-stage biotechnology company on a mission to create breakthroughs for people with difficult-to-treat mental health conditions. Our work is grounded in rigorous science to deliver meaningful outcomes for the patients we serve. Mental health disorders are highly prevalent and estimated to affect more than one billion people globally. The economic burden of these disorders is substantial and is growing rapidly. Between 2009 and 2019, spending on mental health care in the United States increased by more than 50%, reaching $225.0 billion, and a Lancet Commission report estimates that the global economic cost will reach $16.0 trillion by 2030.
In its own words, from its 10-K, filed Mar 6, 2026.
AtaiBeckley against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +137% against the peers' median +10%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AtaiBeckley | Q2 2026 | $1.7M | +137% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: AtaiBeckley 10-Q on SEC EDGAR · CIK 2081043 · Pharmaceutical Preparations